<!DOCTYPE html><html><head><link rel="stylesheet" href="../displacy.css"></head><body><section class="edgaug_item7" id="edgaug_item7_id">ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This
Management’s Discussion and Analysis of Financial Conditions and Results of Operations and other portions of this report
contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those
anticipated by the forward-looking information. Factors that may cause such differences include, but are not limited to, availability
and cost of financial resources, product demand, market acceptance and other factors discussed in this report under the heading
“Risk Factors”. <mark data-entity="org">This Management’s Discussion and Analysis of Financial Conditions and Results of Operations</mark>
should be read in conjunction with our financial statements and the related notes included elsewhere in this report.</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><mark data-entity="person">Advaxis</mark>,
Inc. (><mark data-entity="person">Advaxis</mark>, or the “Company”) is a clinical-stage biotechnology company focused on the development
and commercialization of proprietary <i>Lm</i> Technology antigen delivery products based on a platform technology that utilizes
live attenuated <i>Listeria monocytogenes</i>, or <i>Lm</i> bioengineered to secrete antigen/adjuvant fusion proteins. These <i>Lm</i>-based
strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy
by accessing and directing antigen presenting cells to stimulate anti-tumor T cell immunity, stimulate and activate the immune
system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in <mark data-entity="gpe">the Tumor Microenvironment</mark>, or
TME, to enable the T cells to attack tumor cells. The Company believes that <i>Lm</i> Technology immunotherapies can complement
and address significant unmet needs in the current oncology treatment landscape. Specifically, their product candidates have the
potential to optimize checkpoint performance, while having a generally well-tolerated safety profile, and most of their product
candidates are immediately available for treatment with a low cost of goods. The Company’s passion for the clinical potential
of <i>Lm</i> Technology is balanced by focus and fiscal discipline and driven towards increasing shareholder value.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 39; Value: 2 -->
<div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"> </td></tr></table></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><mark data-entity="person">Advaxis</mark>,and its collaborators are currently conducting or in the process of winding down clinical studies of <i>Lm</i> Technology immunotherapies
in <mark data-entity="cardinal">four</mark> program areas:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.5in; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="width: 0.25in; padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●
    </font></td>
<td style="font: 10pt Times New Roman, Times, Serif; padding-right: 0.8pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
    Papilloma Virus (“<mark data-entity="work_of_art">HPV”)-associated cancers</mark></font></td></tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><mark data-entity="product">Personalized</mark> neoantigen-directed
    therapies</font></td></tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disease focused
    hotspot/‘off the shelf’ neoantigen-directed therapies</font></td></tr>
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></td>
<td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="padding-right: 0.8pt; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prostate cancer</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All <mark data-entity="cardinal">four</mark> clinical program areas are anchored in the Company’s <i>Lm</i> Technology<sup>TM</sup>, a unique platform designed
for its ability to safely and effectively target various cancers in multiple ways. As an intracellular bacterium, <i>Lm</i> is
an effective vector for the presentation of antigens through both the Major Histocompatibility Complex, or <mark data-entity="org">MHC</mark>, I and II pathways,
due to its active phagocytosis by Antigen Presenting Cells, or APCs. Within the APCs, <i>Lm</i> produces virulence factors which
allow survival in the host cytosol and potently stimulate the immune system.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations for <mark data-entity="date">the Year Ended October 31, 2019</mark> Compared to <mark data-entity="date">the Year Ended October 31, 2018</mark></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
increased <mark data-entity="money">$14.8 million to $20.9 million</mark> for <mark data-entity="date">the year ended October 31, 2019</mark> compared to <mark data-entity="money">$6.1 million</mark> for <mark data-entity="date">the year ended October
31, 2018</mark>. The increase was due to changes in the estimated performance period associated with upfront fees received from Amgen
in conjunction with the collaboration agreement signed in <mark data-entity="date">August 2016</mark>. On <mark data-entity="date">December 10, 2018</mark>, we received a written notice of termination
from Amgen with respect to <mark data-entity="org">the Amgen Agreement</mark>, effective as of <mark data-entity="date">February 8, 2019</mark>. As of the notification date, we adjusted
revenue on a cumulative catch-up basis considering the revised measure of progress for the combined performance obligation
based on the modified service period up to and through the contract termination date resulting in additional revenue of $15.6
million. In addition, during <mark data-entity="date">the year ended October 31, 2019</mark>  the reimbursement of research and development costs of <mark data-entity="money">approximately
$2.0 million</mark> was included in revenue as a result of adoption of <mark data-entity="law">ASC 606</mark>, whereas during <mark data-entity="date">the year ended October 31, 2018</mark>, we recorded
reductions in research and development expenses of <mark data-entity="money">approximately $5.8 million</mark> pertaining to the reimbursement of research and
development costs.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Expenses</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
invest in research and development to advance our <i>Lm</i> technology through our preclinical and clinical development programs.
Research and development expenses for <mark data-entity="date">the years ended October 31, 2019 and 2018</mark> were categorized as follows (in <mark data-entity="cardinal">thousands</mark>):</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended<br/> October 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Increase<br/> (Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td> </td><td> </td>
<td colspan="2"> </td><td> </td><td> </td>
<td colspan="2"> </td><td> </td><td> </td>
<td colspan="2"> </td><td> </td><td> </td>
<td colspan="2"> </td><td> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 44%; text-align: left">HPV-associated cancers</td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">8,139</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">24,272</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(16,133</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(198</td><td style="width: 1%; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left"><mark data-entity="product">Personalized</mark> neoantigen-directed therapy</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,932</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,331</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">601</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">20</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Hotspot/Off-the-Shelf therapies</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">3,221</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">1,204</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,017</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">63</td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left">Prostate cancer</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">863</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">2,844</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(1,981</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(230</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Other expenses</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">11,522</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">32,082</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(20,560</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(178</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="text-align: left; padding-bottom: 1.5pt">Partner reimbursements</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,763</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,763</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td>
<td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Total research &amp; development expense</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">26,677</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">56,970</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">(30,293</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">-114</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Stock-based compensation expense included in research and development expense</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">1,036</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">2,836</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">(1,800</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">-174</td><td style="text-align: left">%</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>HPV-Associated
Cancers (<mark data-entity="org">AXAL</mark>)</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
majority of the HPV-associated research and development costs include clinical trial and other related costs associated with our
axalimogene filolisbac, or(<mark data-entity="org">AXAL</mark>) programs in cervical and head and neck cancers. HPV-associated costs for <mark data-entity="date">the year ended October
31, 2019</mark> decreased <mark data-entity="money">approximately $16.1 million</mark>, or 198%, compared to the same period in 2018. The decrease resulted from the partial
clinical hold by the <mark data-entity="org">FDA</mark> during <mark data-entity="date">the first several months of 2019</mark>, specifically driven by a decrease in investigator payments and
the closing of several sites that did not have patients enrolled. In <mark data-entity="date">May 2019</mark>, we received notification from the <mark data-entity="org">FDA</mark> that the
partial clinical was lifted, and in <mark data-entity="date">June 2019</mark> we announced the closing of our Phase 3 AIM2CERV study in high-risk locally advanced
cervical cancer. We anticipate that we will continue to incur costs associated with the wind down of the study until <mark data-entity="date">late 2020</mark>.
Additionally, a winding down of several studies, including our <mark data-entity="person">Fawcett</mark> study in anal cancer and our <mark data-entity="person">MEDI4736</mark> study in combination
with <mark data-entity="org">MedImmune</mark>’s investigational anti-PD-L1 immune checkpoint inhibitor, <mark data-entity="person">durvalumab</mark>, drove further reduction in costs in <mark data-entity="date">the year ended October 31, 2019</mark> compared to <mark data-entity="date">the year ended October 31, 2018</mark>, We do not anticipate funding any new(<mark data-entity="org">AXAL</mark>)studies.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"> </font></p>
<!-- Field: Page; Sequence: 40; Value: 2 -->
<div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"> </td></tr></table></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><mark data-entity="product">Personalized</mark> Neoantigen-Directed Therapies (<mark data-entity="org">ADXS-NEO</mark>)</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs associated with personalized neoantigen-directed therapies for <mark data-entity="date">the year ended October 31, 2019</mark> increased
approximately <mark data-entity="money">$0.6 million</mark>, or 20%, compared to the same period in 2018. The increase is attributable to the opening of new clinical
sites, the enrollment of patients and manufacturing costs for the clinical supply of such studies. On <mark data-entity="date">October 24, 2019</mark>,
we announced that we have enrolled our last patient in the(<mark data-entity="org">ADXS-NEO</mark>)program in <mark data-entity="org">monotherapy</mark> and will not continue into Part B of
this study. We anticipate that we will incur wind down costs for this study until <mark data-entity="date">late 2020</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><br/>
<mark data-entity="org">Hotspot/Off-the-Shelf Therapies</mark> (<mark data-entity="org">ADXS-HOT</mark>)</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs associated with our hotspot mutation-based therapy for <mark data-entity="date">the year ended October 31, 2019</mark> increased <mark data-entity="percent">approximately
63%</mark> to <mark data-entity="money">$3.2 million</mark> compared to the same period in 2018. The increase is attributable to the startup costs associated with the
initiation of the Phase 1/2 clinical trial in <mark data-entity="date">fiscal 2019</mark>. This is the first study initiated using our(<mark data-entity="org">ADXS-HOT</mark>)construct, which
we believe to be applicable across several tumor types. In <mark data-entity="date">October 2019</mark>, we announced that we completed dosing in Part A of this
study and we anticipate that we will report safety and immune response on the first cohort of our first clinical trial using(<mark data-entity="org">ADXS-HOT</mark>)in <mark data-entity="date">early 2020</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Prostate
Cancer Therapy (<mark data-entity="org">ADXS-PSA</mark>)</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs associated with our prostate cancer therapy for <mark data-entity="date">the year ended October 31, 2019</mark> decreased <mark data-entity="money">approximately
$2.0 million</mark>  or 230%, compared to the same period in 2018. The decrease is attributable to the enrollment in the study ending
in 2017, which resulted in a decrease of the <mark data-entity="date">monthly</mark> operational costs in the study. The Phase 2 study of our(<mark data-entity="org">ADXS-PSA</mark>)compound
is in combination with <mark data-entity="org">KEYTRUDA</mark>® (<mark data-entity="org">pembrolizumab</mark>), <mark data-entity="org">Merck</mark>’s humanized monoclonal antibody against PD-1. During 2019, we
presented updated data from this study which demonstrated an increase in the median overall survival, or <mark data-entity="person">mOS</mark>, to <mark data-entity="date">33.6 months</mark> for
patients in the combination arm of this study. We are in discussions with potential partners on the next step for this therapy.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Expenses</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expenses include salary and benefit costs, stock-based compensation expense, professional fees, laboratory costs and other internal
and external costs associated with our research &amp; development activities. Other expenses for <mark data-entity="date">the year ended October 31, 2019</mark> decreased <mark data-entity="money">approximately $20.6 million</mark>, or 178%, compared to the same period in 2018. The decrease was primarily attributable to
a decrease in salary related expenses, including stock compensation, and travel expenses resulting from cost control measures
put in place beginning in <mark data-entity="date">June 2018</mark>, as well impairment losses recorded on idle fixed assets. In addition, there was a decrease
in laboratory costs, drug manufacturing process validation and drug stability studies due to the work performed supporting our
Marketing Authorization Application, or <mark data-entity="org">MAA</mark>, in <mark data-entity="loc">Europe</mark> in <mark data-entity="date">fiscal year 2018</mark> in support of the filing, which occurred in February
2018 and no similar filing occurred in <mark data-entity="date">fiscal year 2019</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Partner
Reimbursements</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner
reimbursements for <mark data-entity="date">the year ended October 31, 2019</mark> decreased <mark data-entity="money">approximately $5.8 million</mark>  or 100%, compared to the same period
in 2018. During <mark data-entity="date">the year ended October 31, 2019</mark>  the reimbursement of research and development costs of <mark data-entity="money">approximately $2.0 million</mark>
was included in revenue as a result of adoption of <mark data-entity="law">ASC 606</mark>, while during <mark data-entity="date">the year ended October 31, 2018</mark>, we recorded reductions
in research and development expenses of <mark data-entity="money">approximately $5.8 million</mark> pertaining to the reimbursement of research and development
costs.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative Expenses</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses primarily include salary and benefit costs and stock-based compensation expense for employees included
in our finance, legal and administrative organizations. Also included in general and administrative expenses are outside legal,
professional services and facilities costs. General and administrative expenses for <mark data-entity="date">the years ended October 31, 2019 and 2018</mark> were as follows (in <mark data-entity="cardinal">thousands</mark>):</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended<br/> October 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Increase<br/> (Decrease)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2018</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">$</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td>
<td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr>
<tr style="vertical-align: bottom">
<td> </td><td> </td>
<td colspan="2"> </td><td> </td><td> </td>
<td colspan="2"> </td><td> </td><td> </td>
<td colspan="2"> </td><td> </td><td> </td>
<td colspan="2"> </td><td> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 44%; text-align: left">General and administrative expense</td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">12,179</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">19,472</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(7,293</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td>
<td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">(60</td><td style="width: 1%; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
<td> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="text-align: left">Stock-based compensation expense included in general and administrative expense</td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">966</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">4,147</td><td style="text-align: left"> </td><td> </td>
<td style="text-align: left">$</td><td style="text-align: right">(3,181</td><td style="text-align: left">)</td><td> </td>
<td style="text-align: left"> </td><td style="text-align: right">(329</td><td style="text-align: left">)%</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 41; Value: 2 -->
<div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"> </td></tr></table></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses for <mark data-entity="date">the year ended October 31, 2019</mark> decreased <mark data-entity="money">approximately $7.3 million</mark>, or 60%, compared to the
same period in 2018. In <mark data-entity="date">June 2018</mark>, we began instituting measures to control costs for non-essential items in areas that didn’t
support the strategic direction of the company. Consequently, we reduced general and administrative expenses, including
headcount, which resulted in decreases in salaries and stock-based compensation. In addition, there was a decrease in consulting
and professional fees during <mark data-entity="date">the year ended October 31, 2019</mark> compared to <mark data-entity="date">the prior year</mark> due to external strategy and program assessments
performed during <mark data-entity="date">fiscal year 2018</mark> and not recurring in <mark data-entity="date">fiscal year 2019</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
in <mark data-entity="org">Fair</mark> Values</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><br/>
       For <mark data-entity="date">the year ended October 31, 2019</mark>  we recorded non-cash income from changes in the
fair value of the warrant liability of <mark data-entity="money">approximately $2.6 million</mark>. The decrease in the fair value of liability warrants resulted
from a decrease in our share price from $0.56 at October 31, 2018 to $0.32 at October 31, 2019, as well as a decrease in the number
of liability warrants as a result of the warrant exchange (see <i><mark data-entity="product">Loss</mark> on shares issued in settlement of warrants </i>below<i>).</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For <mark data-entity="date">the year ended October 31, 2018</mark>, the Company recorded non-cash income from changes in the fair value of the warrant liability
of <mark data-entity="money">approximately $3.4 million</mark>. The decrease in the fair value of liability warrants resulting from a decrease in our share price
from $0.85 at <mark data-entity="date">September 11, 2018</mark> (the date the liability warrants were issued) to $0.56 at October 31, 2018.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><mark data-entity="product">Loss</mark> on shares issued in settlement of warrants</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
<mark data-entity="date">March 14, 2019</mark>, we entered into private exchange agreements with certain holders of warrants issued in connection with our September
2018 public offering of common stock and warrants. Pursuant to the exchange agreements, we issued 856,865 shares of common stock
to the investors in exchange for warrants on a 1:1 basis. In connection with the warrant exchange, we recorded a loss of <mark data-entity="money">approximately
$1.6 million</mark> for <mark data-entity="date">the year ended October 31, 2019</mark> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and <mark data-entity="org">Capital Resources</mark></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going
Concern and Managements Plans</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to other development stage biotechnology companies, our products that are being developed have not generated significant revenue.
As a result, we have suffered recurring losses and we require significant cash resources to execute our business plans. These
losses are expected to continue for an extended period of time. The aforementioned factors raise substantial doubt about our ability
to continue as a going concern. The accompanying financial statements have been prepared on a going concern basis, which contemplates
the realization of assets and the satisfaction of liabilities in the normal course of business. The financial statements do not
include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities
that might be necessary should we be unable to continue as a going concern within <mark data-entity="date">twelve months</mark> after the date the financial statements
are issued.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
our major sources of cash have comprised proceeds from various public and private offerings of our common stock, debt financings,
clinical collaborations, option and warrant exercises, NOL tax sales, income earned on investments and grants, and interest income.
From <mark data-entity="date">October 2013</mark> through <mark data-entity="date">October 2019</mark>, we raised <mark data-entity="money">approximately $292.2 million</mark> in gross proceeds (<mark data-entity="money">$27.0 million</mark> in fiscal year
2019) from various public and private offerings of our common stock. We have sustained losses from operations in <mark data-entity="date">each fiscal year</mark>
since our inception, and we expect losses to continue for the indefinite future. As of October 31, 2019 and 2018, we had an accumulated
deficit of <mark data-entity="money">approximately $384.3 million and $367.7 million</mark>, respectively, and stockholders’ equity of <mark data-entity="money">approximately $39.5
million and $24.1 million</mark>, respectively.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of October 31, 2019, we had <mark data-entity="money">approximately $32.4 million</mark> in cash and cash equivalents. Management’s plans to mitigate an
expected shortfall of capital and to support future operations include obtaining additional funds through partnerships or strategic
or financing investors and a continued focus on cost control. We expect to have sufficient capital to fund our obligations as
they become due in the ordinary course of business until <mark data-entity="date">at least January 2021</mark>. The actual amount of cash that we will need to
operate is subject to many factors. We have based this estimate on assumptions that may prove to be wrong, and we could use available
capital resources sooner than currently expected. Because of the numerous risks and uncertainties associated with the development
and commercialization of our product candidates, we are unable to estimate the amount of increased capital outlays and operating
expenses associated with completing the development of our current product candidates. The Company has reduced its operating expenses
to <mark data-entity="money">$38.9 million</mark> for <mark data-entity="date">the year ended October 31, 2019</mark> as compared to <mark data-entity="money">$76.4 million</mark> during <mark data-entity="date">the year ended October 31, 2018</mark>, Furthermore,
the Company expects operating expenses to be <mark data-entity="money">approximately $29 million</mark> for <mark data-entity="date">fiscal year 2020</mark>, which includes <mark data-entity="money">approximately $6 million</mark>
in non-recurring costs related to programs that are winding down.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize that we will need to raise additional capital in order to continue to execute our business plan in the future. There
is no assurance that additional financing will be available when needed or that we will be able to obtain financing on terms acceptable
to us or whether we will become profitable and generate positive operating cash flow. If we are unable to raise sufficient additional
funds, we will have to scale back our operations or liquidate assets. In such a scenario, the values we receive for our assets
in liquidation or dissolution could be significantly lower than the values reflected in our financial statements.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></font></p>
<!-- Field: Page; Sequence: 42; Value: 2 -->
<div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"> </td></tr></table></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was <mark data-entity="money">approximately $36.1 million</mark> for <mark data-entity="date">the year ended October 31, 2019</mark> compared to net cash used
in operating activities of <mark data-entity="money">approximately $62.1 million</mark> for <mark data-entity="date">the year ended October 31, 2017</mark>. Net cash used in operating activities
includes spending associated with our clinical trial programs and general and administrative activities. We began instituting
measures to control costs for non-essential items in areas that didn’t support the strategic direction of the company, and
as a result, we reduced operating expenditures significantly.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities was <mark data-entity="money">approximately $1.2 million</mark> for <mark data-entity="date">the year ended October 31, 2019</mark> compared to net cash provided
by investing activities of <mark data-entity="money">$43.6 million</mark> for <mark data-entity="date">the year ended October 31, 2018</mark>, During <mark data-entity="date">fiscal year 2018</mark>  many of our remaining short-term
investment securities matured and a portion of the proceeds were used to fund operating activities. In addition, there was a reduction
in property and equipment purchases during <mark data-entity="date">the year ended October 31, 2019</mark> of <mark data-entity="money">approximately $1.4 million</mark> as compared to <mark data-entity="date">the prior
year</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was <mark data-entity="money">approximately $24.6 million</mark> for <mark data-entity="date">the year ended October 31, 2019</mark> as compared to <mark data-entity="money">$39.2
million</mark> for <mark data-entity="date">the year ended October 31, 2018</mark>, In <mark data-entity="date">fiscal year 2019</mark>. we received net proceeds of <mark data-entity="money">approximately $24.5 million</mark> from
the sales of 13,150,000 shares of our common stock and 13,656,000 pre-funded warrants in public offerings while in fiscal year
2018, we received net proceeds of <mark data-entity="money">approximately $36.5 million</mark> from sales of 1,777,778 shares of our common stock in public
offerings and <mark data-entity="money">approximately $2.7 million</mark> from the sale of 58,776 shares of our common stock in at-the-market transactions.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Off-Balance
Sheet Arrangements</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of October 31, 2019, our total future minimum lease payments under noncancelable operating leases was <mark data-entity="money">approximately $8.3 million</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue
Recognition</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
<mark data-entity="date">November 1, 2018</mark>, the Company adopted ASC Topic 606, Revenue form Contracts with Customers  <mark data-entity="law">ASC 606</mark>,, using the modified retrospective
transition method. Under this method, results for reporting periods beginning on
<mark data-entity="date">November 1, 2018</mark>,are presented under <mark data-entity="law">ASC 606</mark>,
while prior period amounts are not adjusted and continue to be reported in accordance with <mark data-entity="law">ASC Topic 605</mark>, <i>Revenue Recognition
</i>(ASC 605). The Company only applied the modified retrospective transition method to contracts that were not completed as of
<mark data-entity="date">November 1, 2018</mark>, the effective date of adoption for <mark data-entity="law">ASC 606</mark>, This standard applies to all contracts with customers, except for
contracts that are within the scope of other standards. Under <mark data-entity="law">ASC 606</mark>, an entity recognizes revenue when its customer obtains
control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange
for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope
of <mark data-entity="law">ASC 606</mark>, the entity performs the following <mark data-entity="cardinal">five</mark> steps: (i) identify the contract(s) with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies
the <mark data-entity="cardinal">five</mark> step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange
for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the
scope of <mark data-entity="law">ASC 606</mark>, the Company assesses the goods or services promised within each contract, determines those that are performance
obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount
of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is
satisfied.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><mark data-entity="org">The
Company</mark> enters into licensing agreements that are within the scope of <mark data-entity="law">ASC 606</mark>, under which it may exclusively license rights to
research, develop, manufacture and commercialize its product candidates to <mark data-entity="ordinal">third</mark> parties. The terms of these arrangements typically
include payment to the Company of one or more of the following: non-refundable, upfront license fees; reimbursement of certain
costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of
licensed products.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company
performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether
the promised goods or services are performance obligations including whether they are distinct in the context of the contract;
(iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction
price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.
As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a) the number of performance
obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; and (c) the stand-alone
selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv)
above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should
be included in the transaction price as described further below. The transaction price is allocated to each performance obligation
on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations
under the contract are satisfied.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 43; Value: 2 -->
<div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"> </td></tr></table></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
received prior to revenue recognition are recorded as deferred revenue. Amounts expected to be recognized as revenue within <mark data-entity="date">the
12 months</mark> following the balance sheet date are classified as current portion of deferred revenue in the accompanying balance sheets.
Amounts not expected to be recognized as revenue within <mark data-entity="date">the 12 months</mark> following the balance sheet date are classified as deferred
revenue, net of current portion.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exclusive
Licenses.</i> If the license to the Company’s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license
when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether
a performance obligation is distinct from the other performance obligations, the Company considers factors such as the research,
development, manufacturing and commercialization capabilities of the collaboration partner and the availability of the associated
expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from a
performance obligation for its intended purpose without the receipt of the remaining performance obligation, whether the value
of the performance obligation is dependent on the unsatisfied performance obligation, whether there are other vendors that could
provide the remaining performance obligation, and whether it is separately identifiable from the remaining performance obligation.
For licenses that are combined with other performance obligation, the Company utilizes judgment to assess the nature of the combined
performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and,
if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure
of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure
of progress, and thereby periods over which revenue should be recognized, are subject to estimates by management and may change
over the course of the research and development and licensing agreement. Such a change could have a material impact on the amount
of revenue the Company records in future periods.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development Services.</i> The performance obligations under the Company’s collaboration agreements may include research
and development services to be performed by the Company on behalf of the partner. Payments or reimbursements resulting from <mark data-entity="org">the
Company’s</mark> research and development efforts are recognized as the services are performed and presented on a gross basis because
the Company is the principal for such efforts.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><mark data-entity="date">Milestone</mark>
Payments.</i> At the inception of each arrangement that includes research or development milestone payments, the Company evaluates
whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price
using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone
value is included in the transaction price. An output method is generally used to measure progress toward complete satisfaction
of a milestone.><mark data-entity="date">Milestone</mark>
payments that are not within the control of the Company or the licensee, such as regulatory approvals,
are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific,
clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this assessment.
There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur.
At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject
to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a
cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Royalties.
</i>For arrangements that include sales-based royalties, including milestone payments based on a level of sales, which are the
result of a customer-vendor relationship and for which the license is deemed to be the predominant item to which the royalties
relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation
to which some or all of the royalty has been allocated has been satisfied or partially satisfied.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Based Compensation</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 15pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><mark data-entity="org">The
Company</mark> has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed
number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost
of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the
award is measured on the grant date and is then recognized over the requisite service period, usually the vesting period, in both
research and development expenses and general and administrative expenses on the statement of operations, depending on the nature
of the services provided by the employees or consultants.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their
requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option
awards on the date of grant using <mark data-entity="org">the Black Scholes Model</mark> (“<mark data-entity="org">BSM</mark>”) for the remaining awards, which requires that the
Company makes certain assumptions regarding: (i) the expected volatility in the market price of its common stock; (ii) dividend
yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise
(referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation
expense could change materially for future grants.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<!-- Field: Page; Sequence: 44; Value: 2 -->
<div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"> </td></tr></table></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><mark data-entity="org">The
Company</mark> accounts for stock-based compensation using fair value recognition and records forfeitures as they occur. As such, the
Company recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period,
based on the vesting provisions of the individual grants.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Derivative
Financial Instruments</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><mark data-entity="org">The
Company</mark> does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates
all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially
recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements
of operations. For stock-based derivative financial instruments, the Company used the <mark data-entity="org">Monte Carlo</mark> simulation model to value the
derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including
whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative
liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the instrument
could be required within 12 months of the balance sheet date.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Intangible
Assets</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets primarily consist of legal and filing costs associated with obtaining patents and licenses and are amortized on a straight-line
basis over their remaining useful lives which are estimated to be <mark data-entity="date">twenty years</mark> from the effective dates of <mark data-entity="org">the University of Pennsylvania</mark>
(<mark data-entity="org">Penn) License Agreements</mark>, beginning in <mark data-entity="date">July 1, 2002</mark>. These legal and filing costs are invoiced to the Company through Penn and
its patent attorneys.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
has reviewed its long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset
might not be recoverable and its carrying amount exceeds its fair value, which is based upon estimated undiscounted future cash
flows. Net assets are recorded on the balance sheet for patents and licenses related to(<mark data-entity="org">AXAL</mark>)(<mark data-entity="org">ADXS-NEO</mark>)(<mark data-entity="org">ADXS-HOT</mark>)(<mark data-entity="org">ADXS-PSA</mark>)and
ADXS-HER2 and other products that are in development. However, if a competitor were to gain <mark data-entity="org">FDA</mark> approval for a treatment before
us or if future clinical trials fail to meet the targeted endpoints, the Company would likely record an impairment related to
these assets. In addition, if an application is rejected or fails to be issued, the Company would record an impairment of its
estimated book value.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Income
Taxes</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><mark data-entity="org">The
Company</mark> uses the asset and liability method of accounting for income taxes in accordance with <mark data-entity="product">ASC Topic 740</mark>, “<mark data-entity="work_of_art">Income Taxes</mark>.”
Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for <mark data-entity="date">the current year</mark> and
(ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s
financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred
tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the
enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available
positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC
Topic <mark data-entity="product">740-10-30</mark> clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements
and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a
tax position taken or expected to be taken in a tax return. <mark data-entity="product">ASC Topic 740</mark>,10-40 provides guidance on de-recognition, classification,
interest and penalties, accounting in interim periods, disclosure, and transition. The Company will classify as income tax expense
any interest and penalties. The Company has no material uncertain tax positions for any of the reporting periods presented.><mark data-entity="org">The
Company</mark> files tax returns in <mark data-entity="gpe">U.S.</mark> federal and state jurisdictions, including <mark data-entity="gpe">New Jersey</mark>, and is subject to audit by tax authorities
beginning with <mark data-entity="date">the year ended October 31, 2016</mark>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font: 10pt Times New Roman, Times, Serif"> </font></p>
<!-- Field: Page; Sequence: 45; Value: 2 -->
<div style="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
<div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%; text-align: center"> </td></tr></table></div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New
Accounting Standards</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Note 2 to our financial statements that discusses new accounting standards.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="a_012"></a></section><div id="item_end"></div><div id="edgaug_item7_end"></div></body></html>